risankizumab psoriasis
Selected indexed studies
- Risankizumab for the treatment of psoriasis. (Expert Rev Clin Pharmacol, 2019) [PMID:31460804]
- Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. (JAMA, 2020) [PMID:32427307]
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. (Lancet, 2018) [PMID:30097359]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. (2018) pubmed
- Risankizumab for the treatment of psoriasis. (2019) pubmed
- Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. (2020) pubmed
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. (2019) pubmed
- Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. (2019) pubmed
- Risankizumab in moderate-to-severe plaque psoriasis. (2019) pubmed
- Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab. (2025) pubmed
- Risankizumab in the treatment of psoriasis - literature review. (2019) pubmed
- A non-clinical comparative study of IL-23 antibodies in psoriasis. (2021) pubmed
- Risankizumab for the treatment of moderate to severe psoriasis. (2019) pubmed